WATERTOWN, Mass.--(BUSINESS WIRE)--New England Research Institutes, Inc. (NERI), is developing and launching a large, multi-national observational (non-intervention) registry for men with testosterone deficiency, a condition also known as hypogonadism (HG) or androgen deficiency. The Registry of Hypogonadism in Men (RHYME) will examine the natural history, progression, and current treatment options for the disease. In particular, it will examine the association between testosterone deficiency, testosterone therapy and prostate health. With primary funding from Bayer Schering Pharma AG, approximately 1,000 men at 20 clinical research sites in Europe, and possibly an additional 200 men at 10 sites in North America, will participate in the registry for a minimum of two years.
